Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12612000098831
Ethics application status
Approved
Date submitted
9/01/2012
Date registered
20/01/2012
Date last updated
23/01/2012
Type of registration
Retrospectively registered
Titles & IDs
Public title
DNA damage and Nutritional Profile of ApoE4 carriers, the Major Genetic Risk Factor for Alzheimer’s Disease
Query!
Scientific title
DNA Damage In Cells of Human ApoE4 Carriers and Prevention In vitro By Nutritional Supplementation with Lipophilic Antioxidants and Fatty Acids
Query!
Secondary ID [1]
279694
0
NIL
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease
285524
0
Query!
Condition category
Condition code
Neurological
285712
285712
0
0
Query!
Alzheimer's disease
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
This study aims to determine the DNA damage, lipid and micronutrient profile of ApoE4 carriers compared to non-carriers, and to determine if DNA damage in lymphocytes of ApoE4 carriers can be prevented with nutritional supplementation. A single fasted blood and cheek cell sample will be collected to determine DNA, micronutrient and fat content status, which may be associated with Alzheimer's disease. Dietary and lifestyle questionnaires and a short cognitive assessment will also be administered to measure mineral and vitamin intake and assess any lifestyle activities that may impact upon Alzheimer disease and dementia risk. All samples will be collected and questionnaires performed during the single visit. No dietary or drug treatment is involved. Recruitment will occur over approximately 5-6 months or until target sample size has been reached.
Query!
Intervention code [1]
283985
0
Not applicable
Query!
Comparator / control treatment
None
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
286238
0
Determine DNA damage, micronutrient and lipid profile of ApoE4 carriers compared to non-carriers using the cytokinesis block micronucleus assay.
Query!
Assessment method [1]
286238
0
Query!
Timepoint [1]
286238
0
Only one sample collection is involved. Samples are set up fresh to determine DNA damage and lipid profile of the volunteers.
Query!
Secondary outcome [1]
295430
0
To determine if nutritional supplementation with lipophilic antioxidants and omega-3 fatty acids, in vitro can prevent DNA damage in ApoE4 carriers compared to non-carriers.
Query!
Assessment method [1]
295430
0
Query!
Timepoint [1]
295430
0
This is performed in the lab on lymphocytes isolated from the blood, once the DNA damage, micronutrient and lipid profiles have been established.
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria
Aged 35-65 years; Healthy; Non-smokers; Male & Female
Query!
Minimum age
35
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Exclusion Criteria:
Mini-mental State Examination (MMSE) score of less than 20. (short mental examination); Currently diagnosed with AD or Mild cognitive impairment; On Medication for life threatening diseases (i.e. chemotherapy); Taking mineral and vitamin supplements above the RDA level on a daily basis; Taking fish oil and antioxidant supplements investigated in the study; Unable to understand the study protocol
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
10/12/2011
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
200
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
284473
0
Government body
Query!
Name [1]
284473
0
Commonwealth Scientific and Industrial Research Organisation
Query!
Address [1]
284473
0
Gate 13, Commonwealth Scientific and Industrial Research Organisation, Kintore Avenue, South Australia, Adelaide 5000
Query!
Country [1]
284473
0
Australia
Query!
Primary sponsor type
Government body
Query!
Name
Commonwealth Scientific and Industrial Research Organisation
Query!
Address
Gate 13, Commonwealth Scientific and Industrial Research Organisation, Kintore Avenue, South Australia, Adelaide 5000
Query!
Country
Australia
Query!
Secondary sponsor category [1]
283399
0
None
Query!
Name [1]
283399
0
Query!
Address [1]
283399
0
Query!
Country [1]
283399
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Summary
Brief summary
Alzheimer’s disease (AD) is the most common form of dementia, currently affecting at least 35 million people worldwide and expected to double every 20 years. The risk of acquiring Alzheimer’s doubles every five years after the age of 65 and may be affected by common alterations in the fat transporter gene (APOE). The brain contains large proportions of fats such as cholesterol and omega-3 fatty acids. APOE plays a crucial role in maintaining healthy fat distribution such as cholesterol and omega-3 fatty acids, as well as brain cell repair and scavenging of toxins. Common alterations in the APOE gene, may directly or indirectly increase DNA damage and accelerate brain aging and degeneration. This disease is currently considered incurable and greatly highlights the need for preventative measures and therapeutic interventions, such as nutritional supplementation, that may improve DNA stability and mental health.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
33607
0
Query!
Address
33607
0
Query!
Country
33607
0
Query!
Phone
33607
0
Query!
Fax
33607
0
Query!
Email
33607
0
Query!
Contact person for public queries
Name
16854
0
Julia Weaver
Query!
Address
16854
0
Gate 13, Commonwealth Scientific and Industrial Research Organisation, Kintore Avenue, South Australia, Adelaide 5000
Query!
Country
16854
0
Australia
Query!
Phone
16854
0
+61 08 83038976
Query!
Fax
16854
0
Query!
Email
16854
0
[email protected]
Query!
Contact person for scientific queries
Name
7782
0
Professor Michael Fenech
Query!
Address
7782
0
Gate 13, Commonwealth Scientific and Industrial Research Organisation, Kintore Avenue, South Australia, Adelaide 5000
Query!
Country
7782
0
Australia
Query!
Phone
7782
0
+61 08 8303 8880
Query!
Fax
7782
0
Query!
Email
7782
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF